A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer

Inclusion Criteria: * 18-70 years * Obtain an informed consent form voluntarily signed by the patient themselves * patients with Unresectable Pancreatic Cancer confirmed by Histopathology * Patients who either: 1) have received standard first-line treatments, proven ineffective or causing intolerable adverse effects; or 2) have not received the standard first-line treatments and voluntarily opt for Autologous Drug-Loaded Neutrophils (NeuMed)-based therapy * EOCG score ≤ 2 and expected survival time ≥ 3 months * Liver, kidney and bone marrow functions are basically normal Exclusion Criteria: * Patients who required anti coagulant therapy * Patients with active infectious diseases or a history of bone marrow or organ transplantation * Patients with autoimmune diseases or autoinflammatory diseases * Patients with a history of severe cardiovascular or cerebrovascular diseases or interstitial lung disease or non-infectious pneumonia * Patients who have received live vaccines within 30 days prior to enrollment * Patients with no response to bone marrow mobilization * Other patients deemed unsuitable for enrollment by the investigator